Owlet, Inc. (OWLT) Stock Analysis and Metrics

Owlet

NYSE: OWLT

$5.25 ▼ -0.05 (-0.94%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap147.80 Mn

P/E-2.97

P/S1.38

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)15.30 Mn

Revenue Growth (1y) (Qtr)6.41

Add ratio to table…

About

Owlet, Inc. is a digital parenting platform company that provides real-time data and insights to parents through connected hardware products and associated mobile applications. The company designs, develops, and sells wearable infant monitoring devices that track vital signs such as heart rate and oxygen levels, aiming to empower parents with information to feel more confident and rested. Its core mission centers on supporting infant health and parental well-being through technology-driven solutions in the consumer baby care market.

Owlet generates revenue primarily from the sale of its hardware products, including the Dream Sock and Dream Duo infant monitors, which are sold directly to consumers through online retail channels and third-party distributors. A growing portion of revenue comes from the Owlet360 subscription service, which launched in January 2025 and provides parents with enhanced app features, sleep insights, and wellness tracking through a recurring monthly fee. Revenue is recognized when control of goods or services transfers to the customer, reflecting the expected consideration in exchange for those products or services.

The company operates through the following segments:

• Product Sales: This segment includes the design, manufacturing, and sale of wearable infant monitoring devices such as the Dream Sock and Dream Duo, which track heart rate, oxygen levels, and sleep patterns for infants, along with associated hardware accessories and fulfillment services.

• Subscription Services: This segment encompasses the Owlet360 platform, a software-based service offering parents advanced analytics, sleep coaching, and wellness tracking through a mobile application, delivered on a recurring basis to enhance the core product experience and drive ongoing customer engagement.

Owlet operates in the competitive consumer baby technology market, where it faces competition from other infant monitoring brands such as Nanit, Miku, and Angelcare, as well as broader smart nursery players. Its competitive advantage lies in being one of the first to market with FDA-cleared wearable pulse oximetry technology for infants, combined with a strong direct-to-consumer brand and a growing ecosystem of integrated hardware and software offerings that differentiate it through data-driven parenting insights.

The company serves individual consumers, primarily parents and caregivers of infants and young children, who purchase its products through direct-to-consumer online platforms and retail partners. Its customer base consists of households seeking technology-assisted solutions for infant monitoring and parental reassurance, with no specific institutional or commercial customer names disclosed in the filing.

Investment Thesis

▲ Bull case

Owlet's strategic pivot toward high-margin recurring revenue streams is creating a structural shift in its business model that the market is underestimating, with subscription gross margin expanding to 67.4% in Q1 FY26 and driving overall gross margin expansion of 80 basis points year-over-year despite a 480-basis-point tariff headwind. The company has achieved a 34% penetration rate among U.S. Dream Sock users for its Owlet360 subscription platform, with monthly recurring revenue reaching $1 million at quarter-end—a figure that compounds predictably as the company leverages its unique pediatric health data set to extend customer lifetime value. Management explicitly stated that the Dream Sight subscription feature set is critical for extending LTV, noting that families use cameras throughout toddler years, which transforms what was historically a one-time hardware sale into a multi-year subscription relationship. This evolution is further reinforced by the launch of AI-driven features like Camera Extended Clips and built-in white noise, which integrate the product into nightly sleep routines to foster consistent platform engagement and reduce churn. The market appears to be focusing solely on the near-term revenue guidance reduction to $118–$122 million for FY26 while overlooking how this deliberate exit from lower-margin, high-burden noncore markets (like deferred entries into India, Hong Kong, and Singapore) is actually improving the quality of revenue and accelerating operating leverage. By redirecting resources to core markets where penetration remains low—just over 11% in the U.S. and low single digits in Europe—with underpenetrated opportunities of nearly 20 million children under 24 months, Owlet is positioning itself to scale toward over 1 million new customers annually. The company’s operational discipline, including eliminating non-critical headcount additions and leveraging AI-driven efficiencies, is designed to drive meaningful operating leverage, as evidenced by the raised full-year 2026 adjusted EBITDA guidance of $7–$9 million (250% to 350% growth), which implies a path to sustainable profitability that the market is not pricing in. Early Q2 sell-through trends, with Duo and Dream Sock both exceeding 30% year-over-year growth, validate the strategy and suggest the current full-year guidance may be conservative, particularly as Owlet was the only brand in the U.S. baby monitoring category to grow during a period where the category excluding Owlet declined 19% in dollar terms.
The Owlet OnCall telehealth launch represents a hidden catalyst with significant long-term monetization potential that management intentionally downplayed during the Q&A, framing it as a "test and learn" initiative rather than a near-term revenue driver, despite clear indicators of its strategic importance to the platform’s evolution. Kurt Workman explicitly described OnCall as a "transformational opportunity" that allows parents to communicate directly with pediatricians using Owlet data to empower home care, potentially reducing ER or pediatrician visits, and stated that the insights gained from this initiative would "fuel a significant new revenue stream for the business as we move into next year." This positions OnCall not as an experimental feature but as a deliberate step toward extending customer relationships beyond hardware and subscription into higher-value, stickier pediatric health services—a natural progression from the Owlet360 platform that leverages the company’s data moat and FDA-cleared hardware. The market is likely underestimating how this integration of wellness data with professional oversight could create a defensible, high-margin service tier that increases LTV and reduces churn, especially given that the highest rate of healthcare utilization occurs in the first years of life. Furthermore, the strong international traction—such as nearly 9% newborn penetration in the Czech Republic and similar trajectories in the U.K., Germany, France, and Australia—combined with the recent launch of Dream Sight and Dream Duo 3 across Australia and New Zealand, reveals a scalable global opportunity in core European markets that management has prioritized over riskier emerging market entries. By deferring lower-ROI projects outside the 0–24-month segment and focusing on high-value geographies where they already have category leadership, Owlet is building a profitable growth engine that the market is failing to recognize as a structural advantage rather than a temporary tactical shift.

Owlet's strategic pivot toward high-margin recurring revenue streams is creating a structural shift in its business model that the market is underestimating, with subscription gross margin expanding to 67.4% in Q1 FY26 and driving overall gross margin expansion of 80 basis points year-over-year despite a 480-basis-point tariff headwind. The company has achieved a 34% penetration rate among U.S. Dream Sock users for its Owlet360 subscription platform, with monthly recurring revenue reaching $1 million at quarter-end—a figure that compounds predictably as the company leverages its unique pediatric health data set to extend customer lifetime value. Management explicitly stated that the Dream Sight subscription feature set is critical for extending LTV, noting that families use cameras throughout toddler years, which transforms what was historically a one-time hardware sale into a multi-year subscription relationship. This evolution is further reinforced by the launch of AI-driven features like Camera Extended Clips and built-in white noise, which integrate the product into nightly sleep routines to foster consistent platform engagement and reduce churn. The market appears to be focusing solely on the near-term revenue guidance reduction to $118–$122 million for FY26 while overlooking how this deliberate exit from lower-margin, high-burden noncore markets (like deferred entries into India, Hong Kong, and Singapore) is actually improving the quality of revenue and accelerating operating leverage. By redirecting resources to core markets where penetration remains low—just over 11% in the U.S. and low single digits in Europe—with underpenetrated opportunities of nearly 20 million children under 24 months, Owlet is positioning itself to scale toward over 1 million new customers annually. The company’s operational discipline, including eliminating non-critical headcount additions and leveraging AI-driven efficiencies, is designed to drive meaningful operating leverage, as evidenced by the raised full-year 2026 adjusted EBITDA guidance of $7–$9 million (250% to 350% growth), which implies a path to sustainable profitability that the market is not pricing in. Early Q2 sell-through trends, with Duo and Dream Sock both exceeding 30% year-over-year growth, validate the strategy and suggest the current full-year guidance may be conservative, particularly as Owlet was the only brand in the U.S. baby monitoring category to grow during a period where the category excluding Owlet declined 19% in dollar terms.
The Owlet OnCall telehealth launch represents a hidden catalyst with significant long-term monetization potential that management intentionally downplayed during the Q&A, framing it as a "test and learn" initiative rather than a near-term revenue driver, despite clear indicators of its strategic importance to the platform’s evolution. Kurt Workman explicitly described OnCall as a "transformational opportunity" that allows parents to communicate directly with pediatricians using Owlet data to empower home care, potentially reducing ER or pediatrician visits, and stated that the insights gained from this initiative would "fuel a significant new revenue stream for the business as we move into next year." This positions OnCall not as an experimental feature but as a deliberate step toward extending customer relationships beyond hardware and subscription into higher-value, stickier pediatric health services—a natural progression from the Owlet360 platform that leverages the company’s data moat and FDA-cleared hardware. The market is likely underestimating how this integration of wellness data with professional oversight could create a defensible, high-margin service tier that increases LTV and reduces churn, especially given that the highest rate of healthcare utilization occurs in the first years of life. Furthermore, the strong international traction—such as nearly 9% newborn penetration in the Czech Republic and similar trajectories in the U.K., Germany, France, and Australia—combined with the recent launch of Dream Sight and Dream Duo 3 across Australia and New Zealand, reveals a scalable global opportunity in core European markets that management has prioritized over riskier emerging market entries. By deferring lower-ROI projects outside the 0–24-month segment and focusing on high-value geographies where they already have category leadership, Owlet is building a profitable growth engine that the market is failing to recognize as a structural advantage rather than a temporary tactical shift.

▼ Bear case

Owlet’s operating leverage remains fragile and is at risk of deterioration due to uncontrolled operating expense growth, which rose to 79% of revenue in Q1 FY26 from 66% in the prior year—a troubling trend that management attributed to higher compensation and stock-based compensation costs from prior-year headcount additions, despite claiming to have paused new hiring outside critical positions. The company reported an operating loss of $5.5 million in Q1 FY26, more than doubling the $2.7 million loss from Q1 FY25, and while adjusted EBITDA came in at the high end of guidance at negative $1.5 million, this was achieved only because tariff impacts were partially offset by a favorable shift in revenue mix toward higher-margin subscription—a factor that may not be sustainable if subscription growth decelerates or if hardware sales face renewed pressure. The market may be overlooking the fact that Owlet’s guidance assumes a 15% tariff rate for the remainder of FY26, but if trade tensions escalate or shift unfavorably, the 480-basis-point gross margin drag seen in Q1 could persist or worsen, directly undermining the company’s path to profitability. Furthermore, the company’s decision to defer entries into India, Hong Kong, and Singapore—while framed as a focus on higher-return markets—could signal growing challenges in international expansion, particularly if core European markets fail to deliver the expected penetration growth, leaving Owlet overexposed to a U.S. market where baby monitoring category trends remain volatile and dependent on promotional cycles. The assertion that Owlet was the only brand to grow in a declining category (where others fell 19%) is misleading without context; Q1 inherently has low promotional activity following holidays, and management admitted customers are delaying purchases in anticipation of events like Mother’s Day and Pride Day, suggesting the 11% year-over-year revenue growth may reflect timing advantages rather than fundamental demand strength.
The company’s reliance on extending customer lifetime value through multi-child, multi-year subscription models is built on unproven behavioral assumptions that pose significant execution risk, particularly regarding whether parents will maintain engagement with Owlet360 beyond the first child or renew subscriptions for subsequent children. While management cited internal benchmarks being surpassed and expressed optimism about achieving a 4-year family subscription life cycle, they provided no concrete cohort retention data beyond stating they are in a "monthly single-digit churn range"—a metric that lacks specificity and could mask deteriorating trends if not broken down by cohort or tenure. The Dream Sock NPS of 77 and blended NPS of 71 are strong, but NPS alone does not predict renewal behavior, especially in a discretionary spending category where parents may opt for lower-cost alternatives as children age. Additionally, the push to integrate AI-driven features like Dream Sight’s Extended Clips and white noise into the subscription bundle risks feature bloat or complexity that could deter adoption if not seamlessly executed, and the company’s claim that AI will "unlock massive growth" over the next few years remains vague and unsubstantiated by near-term milestones. The telehealth initiative, while promising, is still in early testing phases with no clear monetization path, pricing strategy, or partnership model disclosed, and regulatory hurdles in telehealth—particularly around data privacy, cross-state licensing, and reimbursement—could delay or complicate scaling. Finally, the company’s liquidity position, while seemingly strong with $39.4 million in total quarter-end liquidity, includes a $6.3 million term loan principal balance, and with operating cash flow negative due to sustained losses, there is a risk that Owlet may need to tap its credit line or seek additional financing if profitability improvements are delayed, potentially leading to dilution or increased financial leverage that the market is not currently pricing in.

Owlet’s operating leverage remains fragile and is at risk of deterioration due to uncontrolled operating expense growth, which rose to 79% of revenue in Q1 FY26 from 66% in the prior year—a troubling trend that management attributed to higher compensation and stock-based compensation costs from prior-year headcount additions, despite claiming to have paused new hiring outside critical positions. The company reported an operating loss of $5.5 million in Q1 FY26, more than doubling the $2.7 million loss from Q1 FY25, and while adjusted EBITDA came in at the high end of guidance at negative $1.5 million, this was achieved only because tariff impacts were partially offset by a favorable shift in revenue mix toward higher-margin subscription—a factor that may not be sustainable if subscription growth decelerates or if hardware sales face renewed pressure. The market may be overlooking the fact that Owlet’s guidance assumes a 15% tariff rate for the remainder of FY26, but if trade tensions escalate or shift unfavorably, the 480-basis-point gross margin drag seen in Q1 could persist or worsen, directly undermining the company’s path to profitability. Furthermore, the company’s decision to defer entries into India, Hong Kong, and Singapore—while framed as a focus on higher-return markets—could signal growing challenges in international expansion, particularly if core European markets fail to deliver the expected penetration growth, leaving Owlet overexposed to a U.S. market where baby monitoring category trends remain volatile and dependent on promotional cycles. The assertion that Owlet was the only brand to grow in a declining category (where others fell 19%) is misleading without context; Q1 inherently has low promotional activity following holidays, and management admitted customers are delaying purchases in anticipation of events like Mother’s Day and Pride Day, suggesting the 11% year-over-year revenue growth may reflect timing advantages rather than fundamental demand strength.
The company’s reliance on extending customer lifetime value through multi-child, multi-year subscription models is built on unproven behavioral assumptions that pose significant execution risk, particularly regarding whether parents will maintain engagement with Owlet360 beyond the first child or renew subscriptions for subsequent children. While management cited internal benchmarks being surpassed and expressed optimism about achieving a 4-year family subscription life cycle, they provided no concrete cohort retention data beyond stating they are in a "monthly single-digit churn range"—a metric that lacks specificity and could mask deteriorating trends if not broken down by cohort or tenure. The Dream Sock NPS of 77 and blended NPS of 71 are strong, but NPS alone does not predict renewal behavior, especially in a discretionary spending category where parents may opt for lower-cost alternatives as children age. Additionally, the push to integrate AI-driven features like Dream Sight’s Extended Clips and white noise into the subscription bundle risks feature bloat or complexity that could deter adoption if not seamlessly executed, and the company’s claim that AI will "unlock massive growth" over the next few years remains vague and unsubstantiated by near-term milestones. The telehealth initiative, while promising, is still in early testing phases with no clear monetization path, pricing strategy, or partnership model disclosed, and regulatory hurdles in telehealth—particularly around data privacy, cross-state licensing, and reimbursement—could delay or complicate scaling. Finally, the company’s liquidity position, while seemingly strong with $39.4 million in total quarter-end liquidity, includes a $6.3 million term loan principal balance, and with operating cash flow negative due to sustained losses, there is a risk that Owlet may need to tap its credit line or seek additional financing if profitability improvements are delayed, potentially leading to dilution or increased financial leverage that the market is not currently pricing in.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password